Edit |   |
---|---|
Antigenic Specificity | CD123, Human |
Clone | REAL270 |
Host Species | Recombinant Human |
Reactive Species | human |
Isotype | n/a |
Format | phycoerythrin (PE) conjugate |
Size | 200 µL |
Concentration | n/a |
Applications | MICS (MACSima Imaging Cyclic Staining), Immunohistochemistry, Immunofluorescence |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | CD123 Antibody, anti-human, PE, REAdye_lease™. Clone REAL270 is an antibody fragment derived from the full CD123 antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAdye_lease Complex to bind markers with high avidity. | Clone REAL270 recognizes the human CD123 antigen, a type I transmembrane glycoprotein, which is also known as IL-3 receptor α-chain and is the primary low-affinity subunit of the IL-3 receptor. CD123 associates with CD131, the common β-chain of the IL-3, IL-5, and GM-CSF receptor, to form the high-affinity IL-3 receptor. The IL-3 receptor is involved in cell signaling for cell growth and differentiation. In peripheral blood, the CD123 antigen is expressed at high levels only on plasmacytoid dendritic cells and basophilic granulocytes but at low levels also on monocytes, eosinophilic granulocytes, myeloid dendritic cells, and subsets of hematopoietic progenitor cells. | CD123 serves as a diagnostic marker for acute myeloid leukemia (AML). | For removal of REAdye_lease fluorochromes for optional relabeling with different fluorochrome-conjugated REAdye_lease antibodies use the REAlease Support Kit (130-120-675). |
Immunogen | n/a |
Other Names | IL3RA, IL3RAY, IL3R, IL3RX, IL3RY, hIL-3Ra, IL-3Rα |
Gene, Accession # | n/a |
Catalog # | 130-121-315 |
Price | $490 |
Order / More Info | CD123, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG |
Product Specific References | Rollins-Raval, M. et al. (2013) CD123 immunohistochemical expression in acute myeloid leukemia is associated with underlying FLT3-ITD and NPM1 mutations. Appl. Immunohistochem. 21 (3): 212-217. |